Business
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Adds dedicated business development leadership to support Tempest’s strategic prioritiesWill lead China outreach and cross-border partnership effortsTo
About this update from Tempest Therapeutics, Inc.
[{"type":"text","content":"Adds dedicated business development leadership to support Tempest’s strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest’s global business development efforts, including strategic partnerships, cross-border licensing and corporate transactions, with a particular focus on expanding Tempest’s outreach and partnering efforts in China. The appointment reflects Tempest’s increasing emphasis on business development as a core strategic priority, including pursuing potential partnerships for its Phase 3-ready small molecule program, amezalpat, and advancing strategic collaborations across its CAR-T portfolio. “We are pleased to welcome Andrew to the Tempest team,” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “Andrew brings deep experience in cross-border licensing, strategic transactions and capital markets, particularly across the United States and Chinese biotech ecosystems. As we prioritize business development, including seeking a partner for our Phase 3-ready amezalpat program and pursuing Chinese development opportunities following regulatory clearance for a pivotal trial, we believe Andrew’s expertise and relationships will be invaluable.” Tempest continues to prioritize strategic partnerships for amezalpat, its Phase 3-ready small molecule program for hepatocellular carcinoma (“HCC”). Tempest previously announced clearance to proceed with a pivotal trial of amezalpat in China, building on alignment with the U.S. Food and Drug Administration (“FDA”) and European Medical Agency (“EMA”) on amezalpat’s Phase 3 study design and positioning the program for potential global development. Tempest believes that these regulatory milestones also create opportunities for regional partnerships and cross-border collaborations. Dr. Fang is a Founding Partner and Principal of YQ Advisors, where he focuses on strategic t...